UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 11 von 13
Datensatz exportieren als...
BibTeX
Rasagiline improves quality of life in patients with early Parkinson's disease
Movement disorders, 2006-05, Vol.21 (5), p.616-623
Biglan, Kevin M.
Schwid, Steven
Eberly, Shirley
Blindauer, Karen
Fahn, Stanley
Goren, Tamar
Kieburtz, Karl
Oakes, David
Plumb, Sandra
Siderowf, Andrew
Stern, Matthew
Shoulson, Ira
2006
Details
Autor(en) / Beteiligte
Biglan, Kevin M.
Schwid, Steven
Eberly, Shirley
Blindauer, Karen
Fahn, Stanley
Goren, Tamar
Kieburtz, Karl
Oakes, David
Plumb, Sandra
Siderowf, Andrew
Stern, Matthew
Shoulson, Ira
Titel
Rasagiline improves quality of life in patients with early Parkinson's disease
Ist Teil von
Movement disorders, 2006-05, Vol.21 (5), p.616-623
Ort / Verlag
Hoboken: Wiley Subscription Services, Inc., A Wiley Company
Erscheinungsjahr
2006
Link zum Volltext
Quelle
Wiley Online Library Journals Frontfile Complete
Beschreibungen/Notizen
The objective of this study was to determine the effects of rasagiline as monotherapy on quality of life (QOL) in patients with early Parkinson's disease (PD). Rasagiline, a potent, second‐generation, irreversible, selective monoamine oxidase B inhibitor improves PD symptoms in patients with early PD. Patients with early untreated PD were randomly assigned to once‐daily rasagiline 1 mg/day, rasagiline 2 mg/day, or placebo in a 6‐month, double‐blind trial (n = 404). At the end of 6 months, patients entered the preplanned, active‐treatment phase in which those receiving 1 mg/day and 2 mg/day of rasagiline continued on their previously assigned dosages and those receiving placebo switched to rasagiline 2 mg/day, while maintaining blinding to treatment assignments. QOL was measured with the Parkinson's Disease Quality of Life questionnaire (PDQUALIF) at 0, 14, 26, and 52 weeks after randomization. Analysis of the change in PDQUALIF scores from baseline to 6 months showed adjusted treatment effects (with 95% confidence interval) favoring rasagiline over placebo of −2.91 units (−5.19, −0.64, P = 0.01) for the 1 mg/day group and −2.74 units (−5.02, −0.45, P = 0.02) for the 2 mg/day. Subscore analysis attributed most of this benefit to the self‐image/sexuality domain. At 12 months (n = 266), with all groups receiving rasagiline for at least 6 months, no significant differences in PDQUALIF scores were seen between groups. Rasagiline improved QOL compared with placebo. This QOL improvement appears to be accounted for primarily by the symptomatic benefit of rasagiline. © 2006 Movement Disorder Society
Sprache
Englisch
Identifikatoren
ISSN: 0885-3185
eISSN: 1531-8257
DOI: 10.1002/mds.20764
Titel-ID: cdi_proquest_miscellaneous_67961671
Format
–
Schlagworte
Aged
,
Analysis of Variance
,
Biological and medical sciences
,
Chi-Square Distribution
,
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
,
Dose-Response Relationship, Drug
,
Double-Blind Method
,
Female
,
Humans
,
Indans - therapeutic use
,
Male
,
Medical sciences
,
Middle Aged
,
Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis
,
Neurology
,
Neuroprotective Agents - therapeutic use
,
Neuropsychological Tests
,
Parkinson Disease - drug therapy
,
Parkinson Disease - psychology
,
Parkinson's disease
,
Quality of Life
,
rasagiline
,
Severity of Illness Index
,
Surveys and Questionnaires
,
Time Factors
,
Treatment Outcome
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX